benefit-risk profile for Hydroxychloroquine in the COVID-19 treatment

An unfavourable benefit-risk profile for Hydroxychloroquine in the COVID-19 treatment

COVID-19 Medication, Global Safety Alerts, Medicinal Product Updates, Pharmacovigilance, Safety Communications, USFDA-United States of America, Voluntary ADR reporting, , , ,

Hydroxychloroquine is an antimalarial class of drug which is used in the treatment and prevention of acute attacks of malaria. It is also used to treat discoid or systemic lupus erythematosus, rheumatic disorders like rheumatoid arthritis, porphyria cutanea tarda and Q fever. Hydroxychloroquine acts by increasing pH within intracellular vacuoles and alter processes such as protein…

Read More

USFDA’s Drug Safety Communication: Caution on COVID-19 medication

Drug Safety Updates, Pharmacovigilance, Safety Communications, , , , , ,

Food and Drug Administration (FDA) in the United States announced a serious safety concern on the use of hydroxychloroquine or chloroquine for the treatment of 2019 Coronavirus Disease (COVID-19) due to abnormal heart rhythms like QT prolongation and ventricular tachycardia. Currently, there are no medicines proven effective for the treatment of COVID-19. On 28‑Mar‑2020, FDA released…

Read More

error: Content is protected !!